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Abstract: Sturge–Weber syndrome has been included in the group of phakomatoses that is 
characterized by hamartomas involving the brain, skin, and eyes. The characteristic facial port-
wine stain, involving the first branch of the trigeminal nerve and the embryonic vasculature 
distribution in this area, leads to several ocular complications of the anterior segment and can 
involve the eyelids and conjunctiva. The posterior segment of the eyes is also affected with 
diffuse choroidal hemangiomas. However, the most frequent ocular comorbidity is glaucoma 
with a prevalence rate ranging from 30%–70%. Glaucoma is related to anterior chamber 
malformations, high episcleral venous pressure (EVP), and changes in ocular hemodynamics. 
Glaucoma can be diagnosed at birth, but the disease can also develop during childhood and in 
adults. The management of glaucoma in Sturge–Weber syndrome patients is particularly chal-
lenging because of early onset, frequently associated severe visual field impairment at the time 
of diagnosis, and unresponsiveness to standard treatment. Several surgical approaches have 
been proposed, but long-term prognosis for both intraocular pressure control and visual func-
tion remains unsatisfactory in these patients. Choroidal hemangiomas may also lead to visual 
impairment thorough exudative retinal detachment and macular edema. Treatment of exudative 
hemangioma complications is aimed at destructing the tumor or decreasing tumor leakage.
Keywords: Sturge–Weber syndrome, glaucoma, choroidal hemangiomas, port-wine stain, 
congenital disease, glaucoma surgery
Introduction
Sturge–Weber syndrome (SWS) has been included in the group of phakomatoses that 
includes neurofibromatosis, Klippel–Trenaunay syndrome, tuberous sclerosis, and von 
Hippel–Lindau syndrome.1 SWS, also known as encephalotrigeminal angiomatosis, is 
a condition that includes leptomemeningeal hemangioma, facial angiomatosis or nevus 
flammeus (also called port-wine stain [PWS]), and ocular pathological changes.2–5 The 
incidence of SWS is ~1:50,000 infants, with no significant difference between males 
and females.6 No hereditary pattern or predisposition has been shown, and no malignant 
transformation has been demonstrated.7,8 Several genes in the 17p1-p13 region, which 
are known to be involved in SWS, are also known to be linked to rare abnormalities 
and syndromes, such as retinitis pigmentosa, cerebral astrocytoma, subglottic stenosis, 
Klippel–Trenaunay–Weber syndrome, and phakomatosis pigmentovascularis.9–13
The embryologic basis of SWS has been reported to be related to an impaired 
development of the cell precursors in the neural crest during the first embryological 
trimester, leading to the characteristic malformations observed in the central nervous 
system, skin, and eyes.3 Happle suggested that somatic mosaic mutations involving 
the skin cause sporadic or scattered birth defects, and the phase of embryonic devel-
opment during which this occurs is fundamental.14 Shirley et al recently published a 
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ground-breaking study where a mutation in the GNAQ gene 
was identified, which leads to stimulation of cell proliferation 
and inhibition of apoptosis.15 The authors found that the muta-
tion is associated with both sporadic PWSs and SWS.15
Diagnosis is easily performed when the classical clini-
cal signs of SWS are present, consisting of unilateral facial 
PWS along the first branch of the trigeminal nerve, hemi-
atrophy, progressive seizures, contralateral hemiparesis, 
mental deficiencies, hemianopia, and ipsilateral glaucoma.16 
However, Waelchli et al showed that the PWS distribution 
may in fact follow the embryonic vasculature distribution 
of the face, rather than the trigeminal nerve.17 Neuroim-
aging techniques help to perform the diagnosis, showing 
gyriform calcifications that engage the parietal and occipital 
lobes, leptomeningeal angiomatosis, and astrogliosis in the 
brain.18 The diagnosis of SWS is based on the presence of 
at least two of the three manifestations of the classic triad 
(leptomeningeal angioma, PWS, and ocular abnormalities). 
However, clinical findings of SWS may vary, showing 
variable neural signs and symptoms with the absence of or 
varying ocular involvement.19
According to the clinical manifestation, SWS is classified 
into four types: 1) presence of brain and facial angioma, with 
or without glaucoma, 2) PWS without brain involvement, 
with or without glaucoma, 3) isolated brain angioma, usually 
without glaucoma, and 4) type 1 associated with systemic 
manifestation such as tuberous sclerosis (Table 1).20
Ocular findings
Approximately 50% of SWS patients show pathologic ocular 
changes, usually ipsilateral to the PWS, involving the eye-
lid, anterior chamber, cornea, choroid, and retina.3–9,13,16,19–21 
The presence of PWS may involve the eyelid and trigger 
pathological alterations in the ocular blood flow. The bulbar 
conjunctiva (frequently at the limbus) may show diffused or 
localized area of pinkish discoloration related to increased 
conjunctival vascularization. Episcleral vessel dilatation can 
be observed in approximately half of SWS patients.21
Several anterior chamber changes have been described in 
SWS including vascular formations in the trabecular mesh-
work near the scleral spur surrounded by large homogeneous 
extracellular matrix, association of the endothelial layer lining 
of Schlemm’s canal with the basal lamina, and presence of 
several villi and giant vacuoles within the endothelial cells 
that appear as transcellular channels.22
These anatomical alterations justify the frequent 
development of glaucoma in 30%–70% of SWS patients.23,24 
Glaucoma in SWS patients shows a bimodal peak of age 
development: an early-onset (congenital) form affecting ~60% 
of patients and a later-onset form during childhood and ado-
lescence (40% of cases).23 Glaucoma in SWS is unilateral and 
is associated with the presence of an ipsilateral PWS,24 which 
most frequently involves both the eyelids (72%) and sometimes 
only the upper eyelid (21%).13 The most frequent form of 
glaucoma in SWS patients is open-angle glaucoma leading to 
progressive visual field loss. However, acute glaucoma attack 
due to chamber angle closure has also been described.25–27 Con-
genital glaucoma is frequently associated with corneal changes 
(25%), including haze, megalocornea, and buphthalmos.21 
Other anterior segment alterations have been described in SWS 
patients including iris heterochromia and cataract.19
The posterior segment of the eye is also involved with 
hemangiomas of the choroid (20%–70% of cases).28 Choroi-
dal hemangiomas can be clinically divided into localized and 
diffuse forms, but it is the diffuse form that typically occurs 
in SWS patients.19,21 Clinically, ophthalmoscopy shows a 
bright red or red–orange color appearance of the fundus, 
related to the increase of well-formed choroidal vessels, while 
hemangiomas appear as diffuse or localized areas with a dark 
red color and a “tomato ketchup” appearance.13 The pres-
ence of choroidal hemangiomas is frequently asymptomatic; 
however, the choroid may become significantly thickened,29 
and an increased risk of glaucoma development has been 
reported in patients with choroidal hemangioma.30
Alteration of the choroidal vessels may lead to severe 
retinal complications and potentially to visual loss. Subretinal 
hemorrhage, retinal degeneration, retinal serous detachment, 
photoreceptor degeneration, cystoid macular edema, macular 
serous detachment, tortuous retinal vessels, and optic disc 
coloboma have been described in SWS patients.21,31
Ophthalmic management
Routine slit lamp examination is sufficient to detect most of 
the alterations typically observed in SWS patients; however, 
if young children cannot cooperate and there is concern for 
visually threatening diseases such as glaucoma, examination 
under general anesthesia may be recquired. Anterior seg-
ment alterations include eyelids, conjunctival and episcleral 
hemangiomas, and corneal changes related to congenital 
glaucoma. Fundus examination by indirect ophthalmoscopy 
Table 1 Classification of Sturge–Weber syndrome
Type Facial  
angioma
Leptomenigeal  
angioma
Glaucoma Systemic  
manifestation
Type i + + ± ±
Type ii + - ± -
Type iii - + ± -
Type iv + + ± +
Notes: +, Present; -, absent; ±, feature can be observed but is not ubiquitous.
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or biomicroscopy shows the typical features of choroidal 
hemangioma as diffuse or rarely localized areas of flat or 
elevated dark retina, and frequently highlights the difference 
in fundus color with respect to the fellow eye. Retinography 
may be also useful in documenting this color difference.
It is mandatory to strictly monitor glaucoma in SWS 
patients. Clinicians can rely on more than one parameter for 
diagnosing and monitoring glaucoma. In very young patients, 
parameters such as axial length and corneal diameter are 
important. Gonioscopy is a simple and useful examination 
to detect iridocorneal angle malformation and to orient the 
diagnosis toward the type of glaucoma. Intraocular pressure 
(IOP) measurement, optic nerve evaluation, as well as visual 
field testing represent the main procedures to diagnose and 
monitor glaucoma progression. The optic nerve head can be 
observed with optical coherence tomography, which is a non-
invasive and relatively rapid method of evaluation in children 
who have difficulty in cooperating due to their young age 
and/or intellectual difficulty linked to diseases or syndromes 
such as the SWS.32,33 Visual field analysis is fundamental in 
evaluating glaucoma progression, but this examination can be 
challenging to perform in children, although with increasing 
age and learning more reliable results can be obtained.34–37
Several instrumental examinations may also improve 
the diagnosis and monitoring of choroidal hemangioma and 
retinal complications, especially in the presence of anterior 
segment opacity, such as in congenital glaucoma. Ultrasonog-
raphy allows to detect choroidal alterations and to evaluate 
their extension, characteristics, and echogenicity. Indocyanine 
green angiography can add useful information on the exten-
sion and intralesional vascularity of the choroid as well as the 
potential detection of arterovenous shunts. Currently, the gold 
standard examination to characterize choroidal and retinal 
morphology is enhanced depth imaging spectral domain opti-
cal coherence tomography, which allows the quantification of 
choroidal thickness as well as the morphology and the caliber 
of dilated choroidal vessels.29,38 Magnetic resonance imaging 
may also be useful to detect broader thickening of the eyes as 
a consequence of diffuse choroidal hemangioma.
It is crucial to plan complete ophthalmic examinations 
in the follow-up of SWS patients in order to avoid visual 
function loss, frequently related to progressive glaucoma, 
and also to detect the onset of retinal complications such as 
exudative detachment.
Glaucoma pathogenesis
Several new hypotheses and factors have been formulated on 
the pathogenic mechanisms leading to the development of 
glaucoma, and several hypotheses have been formulated to 
explain the pathogenic mechanisms leading to the develop-
ment of glaucoma associated with rare conditions.39–41
The main theories on the pathogenesis of glaucoma in 
SWS include the following:
1) A mechanical mechanism related to congenital malforma-
tion of the anterior chamber angle leading to increased 
resistance to aqueous humor outflow: in this case, the iris 
can also not have the flat anterior insertion characteristic 
of the congenital form;24
2) an increase in episcleral venous pressure (EVP) due to 
arteriovenous shunts into the episcleral hemangioma:29 
this theory is based on the observation of a normal angle 
structure, blood within Schlemm’s canal, and more severe 
glaucoma;42–44
3) fluid hypersecretion by either the ciliary body or the 
choroidal hemangioma;45 and
4) abnormal hemodynamics of the episclera and the anterior 
chamber angle due to premature aging of the trabecular 
meshwork–Schlemm’s canal complex, as observed in 
SWS later-onset glaucoma.46
In SWS patients, an increase in EVP, as compared to 
normal eyes, has been reported in glaucoma-affected eyes.42,47 
However, no significant difference in EVP was observed 
between glaucoma-affected and normal eyes in SWS patients, 
suggesting that elevated EVP is only a risk factor for glau-
coma onset.47 Retrobulbar blood flow was also impaired 
in SWS patients, suggesting an increased risk to develop 
glaucoma with aging. However, no significant difference in 
the arterial retrobulbar blood flow was observed between the 
glaucomatous and the normal fellow normal.48,49
Glaucoma pathogenesis in SWS patients is complex, 
including different interlinked mechanisms that change 
their role with aging. Indeed, in congenital and early-onset 
glaucoma forms, angle malformations play a crucial role. 
In late-onset glaucoma, an increase in EVP, probably related 
to progressive hypertrophy and dilatation of the episcleral 
veins as reported for PWS,50 has a major pathogenic role.
A few cases of acute glaucoma attack due to angle closure 
have been described in SWS. Maruyama et al reported a 
case of a patient with SWS who developed acute glaucoma 
associated with posterior scleritis, edema of the ciliary body, 
ciliochoroidal effusion, and anterior rotation of the ciliary 
body.25 In this case, it was hypothesized that the ciliary body 
effusion induced angle closure by moving the iridolenticular 
diaphragm forward, which led to acute glaucoma attack. This 
mechanism of glaucoma induction has also been described 
following the use of the drug topiramate, which is used for 
seizures that can occur in SWS patients with leptomeningeal 
involvement.27 Angle-closure glaucoma in SWS has also been 
Clinical Ophthalmology 2016:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
874
Mantelli et al
described as related to pupil block with or without ectopia 
lentis and pigment dispersion.51,52 In these cases, ultrasound 
biomicroscopy may represent a precious tool to identify and 
characterize the pathogenic mechanism of acute glaucoma 
attack.53
Medical treatment of glaucoma
The main goal of glaucoma treatment is to control IOP and 
to avoid progressive optic nerve damage and visual field loss. 
Both medical and surgical approaches have been performed 
to halt glaucoma progression in SWS patients (Table 2). Due 
to the rare nature of the disease, only small case series have 
been published leading to a relatively low level of evidence 
regarding treatment efficacy. Topical antiglaucoma drugs 
seem to be less efficacious in SWS patients with congenital 
glaucoma, while they represent first-line therapy for patients 
with late-onset glaucoma.44
Ong et al showed that latanoprost eye drops, as adjunc-
tive therapy, were effective in controlling glaucoma in 50% 
of 14 patients with SWS at 1 year of follow-up.54 In line 
with this, Yang et al demonstrated that latanoprost treatment 
induced a significant pressure decrease in 33% (two eyes) 
of SWS glaucoma patients.55 Latanoprost acts by increasing 
uveoscleral outflow, theoretically bypassing the obstacle to 
the passage of aqueous humor due to the increase in EVP. 
However, long-term use of prostaglandins in SWS patients 
should be carefully evaluated since one of the potential side 
effects of these drugs is uveal effusion.
Only a few case reports describe the use of other anti-
glaucoma drugs in patients with SWS, suggesting that treat-
ment with beta-blockers and carbonic anhydrase inhibitors 
is effective in the absence of buphthalmos.56
Wygnanski-Jaffe et al used oral propanolol for treat-
ing glaucoma in SWS patients.57 Systemic propranolol is 
effective in inducing reduction of hemangiomas of the skin, 
orbit, larynx, and eyes.58,59 However, systemic propanolol 
was ineffective in three of four children with SWS-related 
glaucoma.57
A hypothesis to justify the low efficacy of antiglaucoma 
drugs in controlling SWS-related glaucoma is that most of 
these drugs do not affect EVP, highlighting the need for novel 
antiglaucoma medications specifically targeting EPV.
Surgical treatment of glaucoma
Frequently, medical treatment in SWS patients is not suf-
ficient to guarantee a good long-term control of glaucoma; 
therefore, surgical procedures are commonly performed in 
patients under 2 years of age. Goniotomy and trabeculo-
tomy represent the most appropriate surgical procedures 
to overcome the malformed anterior chamber angle under 
4 years of age. However, Saltzmann et al demonstrated that 
trabeculotomy fails to control congenital glaucoma in all 
Table 2 Treatment of Sturge–weber syndrome-associated glaucoma
Author Year Number  
of patients
Type of study Intervention Outcome
Basler and Sowka44 2011 1 Case report Travoprost eye drop Good iOP control
Sharan et al45 2009 24 Retrospective Medical/surgery Good iOP control: 9 mono- and 9 
multi-drug therapy; 10 trabeculectomy  
and 2 valve implant
Ong et al54 2003 14 Retrospective Latanoprost eye drop Good iOP control in 50% at 1 year
Yang et al55
wygnanski-Jaffe et al57
1998
2015
6
4
Prospective
Prospective
Latanoprost eye drop
Oral propranolol
Good iOP control in 33%
Not effective as single treatment:
75% required additional treatment
Saltzmann et al60
Board and Shields61
2012
1981
7
5
Retrospective
Case series
Trabeculectomy–trabeculotomy 
Trabeculectomy
Not effective and high failure rate  
Good iOP control in 20% at 6 months
Agarwal et al62 1993 16 Retrospective Trabeculotomy–trabeculectomy Good iOP control in 61% at 42 months
Mandal65 1999 9 Case series Trabeculotomy–trabeculectomy Good iOP control in all patients at  
1 year
Audren et al67
Hamush et al69
2006
1999
6
10
Retrospective
Case series
Deep sclerectomy
Ahmed valve
Not effective at 26 months  
Good iOP control in 30% at 60 months
Amini et al70 2007 7 Prospective Molteno tube Good iOP control in 43% at 36 months
Naranjo-Bonilla et al71
elgin et al72
2014
2007
1
1
Case report
Case report
ex-Press® implant
ex-Press® implant
Good iOP control at 10 months  
Good iOP control with adjunctive  
trabeculectomy
van emelen et al73 2000 8 Retrospective Medical/surgery Good iOP control in 12% with medical  
therapy alone
Abbreviation: iOP, intraocular pressure.
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patients with SWS.60 These authors suggested to consider 
alternative surgical procedures and closer postoperative 
monitoring due to this significant relative risk of failure.60 
One of the possible explanations of surgery failures in SWS 
children is that goniosurgery does not affect EVP, suggest-
ing that pathogenic mechanisms other than the simple angle 
malformation influence glaucoma progression.
Other surgical approaches include filtering procedures 
such as trabeculectomy, posterior lip sclerotomy,42 and 
trabeculotomy–trabeculectomy,61,62 which bypass the alter-
ated trabecular meshwork–Schlemm’s canal complex, creat-
ing an alternative outflow passage for the aqueous humor, 
independent to the distal episcleral veins. However, filtering 
procedures have been associated with severe complications 
such as expulsive choroidal hemorrhage, bleeding, prolonged 
flat anterior chamber, and high risk of bleb failure.46,63 Intra-
operative use of antimitotic agents such as mitomycin does 
not improve the outcome.64 Therefore, combined procedures 
such as trabeculotomy–trabeculectomy have been suggested 
as the first-line approach in infants and children.61,65
Alternative surgical procedures include nonpenetrating 
sclerectomy, valve drainage implants, and ciliodestructive 
procedures in adults.66,67 Nonpenetrating sclerotomy has been 
shown to have an efficacy similar to trabeculectomy in con-
trolling SWS-related glaucoma, with a lower rate of complica-
tions.67 However, in SWS patients, the presence of episcleral 
hemangioma and angle malformations make this procedure 
extremely difficult and increase the rate of failure.
Valve implant is also a successful method for IOP 
management.68 In SWS, the Ahmed-type valve was shown 
to induce long-term decrease of IOP by improving aqueous 
humor outflow.69 On the other hand, the use of the Molteno 
tube showed an unfavorable outcome due to an elevated 
complication rate in children with SWS.70
Two studies reported that Ex-Press® valve was suc-
cessfully implanted in children with SWS as an elective 
surgical procedure,71 and in the other case, 10 days prior to 
performing trabeculectomy.72 On the other hand, the use of 
the Ex-Press® glaucoma implant in another child with SWS 
was complicated by choroidal detachment, which resolved 
with medical therapy. Lastly, it is worth mentioning that 
cyclocryotherapy has been used successfully in patients 
with SWS and buphthalmos in combination with topical 
antiglaucoma therapy73 or trabeculectomy.74 Nevertheless, 
cyclocryotherapy can be burdened by severe complications 
such as hypotony and phthisis bulbi.74 Unfortunately, some-
times, even with medical and/or surgical treatment glaucoma 
leads to severe visual field damage, visual acuity loss, and 
optic nerve atrophy; only rehabilitation methods can help in 
improving the quality of life of these patients.75–77
Treatment of other ocular 
manifestations
Facial PWSs can be successfully treated by laser. Better 
esthetic results are achieved when treating the lesions local-
ized on the central forehead rather than the lesions on the 
central face. To obtain better results, PWS should be treated 
early since there is a tendency to thickening and nodular 
transformation with aging.78
Laser treatment should be superficial in order to avoid 
potential complications related to a decrease of brain venous 
outflow through PWS vessels, potentially leading to cerebral 
venous deterioration, choroidal vessel dilatation, retinal 
exudative detachment, and increase in IOP.7 Therefore, deep 
photocoagulation and debulking surgery should be avoided 
in the treatment of PWS.7
As previously described, visual loss in SWS patients 
is mainly related to glaucoma development, but choroidal 
hemangiomas may also lead to visual impairment thorough 
exudative retinal detachment and macular edema. The treat-
ment of exudative hemangioma complications is aimed at 
destructing the tumor or at least at decreasing tumor leakage.79 
Several treatments have been proposed including photoco-
agulation, photodynamic therapy (PDT), external beam radio-
therapy, brachytherapy, and anti-vascular endothelial growth 
factor (VEGF). The scopes of these methods are to reduce 
tumor size, induce vessel atrophy, close leaking vessels, and 
induce inhibition of VEGF to ultimately diminish subretinal 
fluid, which causes increased retinal and macular thickness 
as observed with optical coherence tomography.80–82
Confluent photocoagulation causing destruction of the 
tumor has been considered as the most effective treatment 
in reducing leakage.83 However, several complications can 
be observed following intense photocoagulative treatment, 
leading to the proposal of an alternative, less invasive laser 
procedure, such as grid treatment, that is safer but has a higher 
recurrence of subretinal fluid accumulation.84,85
PDT is theoretically the most indicated procedure to 
treat choroidal hemangiomas, inducing vessel atrophy and 
reducing leakage.66 However, currently, only a few cases of 
diffuse choroidal hemangioma have been treated with PDT, 
probably due to the risk of inducing scarring and pigmentary 
changes of the fovea.86
In case of diffuse choroidal hemangioma complicated 
by serous retinal detachment, an alternative treatment is 
external beam radiotherapy.87,88 Clinical improvement 
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has been observed months following the first application 
but recurrence frequently occurs. Repeated applications 
should be carefully evaluated since they can induce several 
complications such as cataract, neuropathy, and radia-
tion retinopathy.87 Exudative retinal detachment related to 
choroidal hemangiomas has also been successfully treated 
using brachytherapy with cobalt-60 and ruthenium-106.89–92 
Intravitreal injection of pegaptanib (an anti-VEGF) has also 
been described in one SWS patient with exudative retinal 
detachment with satisfactory results.93,94
Conclusion
Glaucoma is the most common ocular complication in 
SWS. The most frequent form is congenital glaucoma, but 
it can also occur in children and adults, making careful 
ophthalmic follow-up of SWS patients mandatory. Indeed, 
glaucoma secondary to SWS is a challenging disease due to 
its early development and poor response to standard medi-
cal treatment.
Surgery is frequently required to obtain long-term control 
of IOP in order to avoid visual function loss. However, sev-
eral severe complications related to surgical procedures have 
been described in these patients, including choroidal effusion, 
expulsive hemorrhage, and exudative retinal detachment. 
Moreover, in SWS, the surgical success rate is the lowest 
among secondary glaucomas, since surgical failure, uncon-
trolled IOP, and low vision outcomes have been frequently 
reported.45,60,61 To date, despite the wide range of available 
medical and surgical approaches to treat both the congenital 
and late-onset forms of glaucoma, the development of this 
ocular complication still represents the worst prognostic 
factor for vision loss in SWS patients.
Choroidal hemangiomas are present in 20%–70% of cases, 
and the choroid may become significantly thickened and can be 
associated with an increased risk of glaucoma development.29 
Choroidal hemangiomas may be asymptomatic; however, 
severe forms may lead to visual impairment thorough exuda-
tive retinal detachment and macular edema. The treatment of 
exudative complications is aimed at destructing the tumor or 
at least at decreasing tumor leakage.
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